Histidine alpha-ketoglutaric acid

Synopsis

Histidine Alpha-Ketoglutaric Acid

1. Identity, Chemical Nature, and Common Names

Histidine alpha-ketoglutaric acid — also rendered as histidine alpha-ketoglutarate, L-histidine alpha-ketoglutarate, L-histidine AKG, and L-histidine-alpha ketoglutaric acid — is a compound formed by combining the essential amino acid L-histidine with alpha-ketoglutaric acid (alpha-ketoglutarate, AKG; also known as 2-oxoglutaric acid or 2-oxopentanedioic acid). The ingredient is also listed under the synonyms l-histidine akg, l-histidine alpha ketoglutaric acid, l-histidine-alpha ketoglutaric acid, and histidine alphaketoglutarate.

Histidine alpha-ketoglutarate is a dietary supplement that is a combination of the amino acid histidine and alpha-ketoglutarate, a salt of glutaric acid. In chemical terms, the compound is an amino-acid salt or co-crystal in which the basic amino acid L-histidine is paired with the dicarboxylic keto acid alpha-ketoglutaric acid. Histidine is an essential amino acid involved in protein synthesis, buffering, and as a precursor for important biomolecules such as histamine. Alpha-ketoglutaric acid is a key intermediate in the Krebs cycle, central to cellular energy production and amino acid metabolism.

Structurally, histidine contains an α-amino group, a carboxylic acid group, and an imidazole side chain. Under physiological conditions, the amino group is protonated and the carboxylic group is deprotonated. The imidazole ring is responsible for the proton buffering, metal ion chelating, and antioxidant properties. Alpha-ketoglutarate (AKG), as an endogenous intermediary metabolite in the Krebs cycle, is a molecule involved in multiple metabolic and cellular pathways.

The pairing of the two molecules into a single salt form is principally an industrial/formulation strategy. By forming a salt with alpha-ketoglutarate, histidine's bioavailability may be enhanced, and the combination may provide synergistic benefits. It should be noted, however, that no independent regulatory body or pharmacopeia had, as of the available literature, issued a specific monograph for histidine alpha-ketoglutaric acid as a distinct chemical entity separate from its two constituent components.

2. Natural Sources

The two constituent molecules occur naturally and ubiquitously in living organisms and food.

Histidine

The primary dietary sources of histidine are animal products with high protein content, such as beef, chicken, and fish. A particularly high content, 109 mg/kg, is found in dried flakes of Bonito tuna (Katsuwonus pelamis). Slightly lower levels of histidine can be found in vegetable protein sources, such as beans, peas, and soybeans. Histidine also accumulates in skeletal muscle in the form of the dipeptides carnosine (β-alanyl-L-histidine) and anserine (β-alanyl-1-methyl-L-histidine). Carnosine and anserine are dipeptides mainly found in skeletal muscle and brain of many vertebrates, and particularly high concentrations are observed in chicken pectoral muscles.

Alpha-Ketoglutaric Acid

Alpha-ketoglutaric acid is produced endogenously in all aerobic organisms as an intermediate of the tricarboxylic acid (TCA) cycle. AKG is a chemical that naturally occurs in the body, where it plays an important role in many processes. It is not a significant standalone component of ordinary foods the way amino acids or vitamins are; rather, it is present at trace concentrations as an intracellular metabolic intermediate and can be obtained commercially by chemical synthesis or fermentation for use in supplements and pharmaceutical preparations.

3. Common Forms and Preparations

As a dietary supplement ingredient, histidine alpha-ketoglutaric acid appears most commonly in the following forms:

Capsules and tablets: Standalone supplements or as part of multi-ingredient formulations, particularly amino acid complexes and sports recovery products.
Powder blends: Added to protein powders, pre-workout formulas, and amino acid blends.
Functional food additions: Histidine alpha-ketoglutarate is used as a dietary supplement in the food industry. It is used to enhance the flavor and nutritional value of food products, as well as to improve the texture and shelf life of certain foods.

Among the broader family of amino acid alpha-ketoglutarate salts, related compounds such as arginine alpha-ketoglutarate (AAKG) and ornithine alpha-ketoglutarate (OKG) have a longer established history in clinical nutrition. Arginine α-ketoglutarate, also known as arginine 2-oxoglutarate, is an organic salt which possesses a number of physiological uses. The histidine variant follows the same structural logic but has a more limited body of independent human clinical research.

The most clinically recognized formulation containing both histidine and ketoglutarate in a pharmaceutical context is histidine-tryptophan-ketoglutarate (HTK) solution (also marketed as Custodiol® or Bretschneider solution), an organ preservation and cardioplegia solution. Histidine-tryptophan-ketoglutarate (HTK) is a high-flow, low-potassium preservation solution used for organ transplantation. The solution was initially developed by Hans-Jürgen Bretschneider. The relationship between the HTK pharmaceutical solution and the oral dietary supplement form of histidine alpha-ketoglutaric acid is conceptual — they share constituent molecules — but their formulations, concentrations, routes of administration, and clinical indications are entirely different.

4. Traditional and Historical Use

As a specific pre-formed salt, histidine alpha-ketoglutaric acid has no documented history of traditional use in indigenous or pre-modern medicine, as it is a chemically defined synthetic entity. Its traditional history must therefore be traced through the separate histories of its two constituent molecules.

Histidine in Early Medical and Nutritional Use

Historically, histidine has been valued in both traditional and modern medicinal contexts for its role in supporting growth, tissue repair, and immune function. In early nutritional therapies, histidine-rich remedies were used to promote recovery from illness and bolster overall vitality, particularly in populations with increased protein requirements such as children and convalescents.

In the 20th century, histidine became an object of early clinical investigation. Initially, HIS was shown to treat rheumatoid arthritis and anaemia in patients with chronic renal failure. The first formally documented clinical uses of L-histidine as a therapeutic supplement arose in the 1970s, when researchers published studies on its application in these two conditions. A randomized, placebo-controlled, double-blind trial of L-histidine for rheumatoid arthritis was published as early as 1977 (Pinals et al., J. Rheumatol. 1977;4:414–419), and a study on histidine for treatment of uraemic anaemia appeared in the British Medical Journal in 1973 (Giordano et al., Br. Med. J. 1973;4:714–716). HIS has been used in therapy of rheumatoid arthritis and anemia of patients with chronic renal failure.

Alpha-Ketoglutarate in Clinical Nutrition

Alpha-ketoglutaric acid has a legacy in clinical nutrition for its ability to support energy production and protein synthesis. It has been used in combination with other amino acids to improve recovery in surgical and critical care patients. Historically, alpha-ketoglutarate has been used in clinical settings as a component of preservation solutions for organ transplantation, demonstrating its ability to support cellular viability under stress.

Studies conducted in 1977 revealed the ability of arginine alpha-ketoglutarate to enhance hepatic detoxification capacity when administered in high dosage to patients with liver cirrhosis (Muting et al., MMW Munch Med Wochenschr, 119(16):535-8). Its effects were marked by a significant decrease in the level of plasma ammonia and free serum phenols.

The medicinal use of the HTK solution for cardiac surgery and organ preservation — a context in which both histidine and ketoglutarate play central pharmacological roles — was established in the 1970s. Histidine–tryptophan–ketoglutarate (HTK) solution (Custodiol/Bretschneider) is an intracellular cardioplegic solution, introduced in the 1970s. The HTK solution was initially used to preserve organs for transplantation, thereafter, it was used in cardioplegia.

5. Key Constituents and Active Compounds

Because histidine alpha-ketoglutaric acid is itself a two-component molecule, its pharmacological profile is best described by the well-characterized properties of each constituent.

5.1 L-Histidine: Biochemical Properties

This amino acid is nutritionally vital for mammals, possessing distinct biochemical and physiological characteristics; these properties give a strong theoretical rationale for the use of histidine as a versatile dietary supplement for various health issues.

The imidazole ring of histidine is its primary functional feature. This ring has a pKa close to physiological pH (~6.0), making histidine uniquely capable of accepting and donating protons under physiological conditions. This underlies histidine's roles as a:

Proton buffer: HTK solution is based on the principle of inactivating organ function by withdrawal of extracellular sodium and calcium, together with intensive buffering of the extracellular space by means of histidine/histidine hydrochloride, so as to prolong the period during which the organs will tolerate interruption of oxygenated blood.
Antioxidant: Many recent studies have demonstrated the therapeutic efficacy of "pharmacologic" doses of L-histidine in animal models of inflammatory conditions, particularly gastrointestinal conditions and cardiac ischemia-reperfusion injury, and have specifically linked the anti-inflammatory capabilities of histidine to its ability to scavenge toxic oxygen species. The maintenance of histidine pools, therefore, may contribute to the body's physiologic antioxidant capacity.
Metal ion chelator: The imidazole ring enables histidine to chelate transition metal ions, which can either promote or inhibit oxidative reactions depending on context. Cold storage and the amino acid histidine has been found to increase intracellular levels of redox-active chelatable iron — a feature noted as a potential limitation in some HTK formulations.
Histamine precursor: Histamine is formed by the decarboxylation of HIS by L-histidine decarboxylase (EC 4.1.1.22) found in many tissues. This pathway connects histidine to immune signaling, gastric secretion, and neurotransmission.
Gluconeogenic amino acid: Histidine is a gluconeogenic amino acid. It is degraded by conversion to glutamate, and then oxidised to alpha-ketoglutarate by glutamate dehydrogenase.

5.2 Alpha-Ketoglutaric Acid: Biochemical Properties

Alpha-ketoglutarate (AKG), an endogenous intermediary metabolite in the Krebs cycle, is a molecule involved in multiple metabolic and cellular pathways. It functions as an energy donor, a precursor in the amino acid biosynthesis, a signalling molecule, as well as a regulator of epigenetic processes and cellular signalling via protein binding.

TCA cycle intermediate: α-Ketoglutarate (α-KG), a central metabolite in the tricarboxylic acid (TCA) cycle, is a required cofactor for α-KG-dependent dioxygenases that regulate diverse cellular processes.
Epigenetic regulator: These include histone, DNA, and RNA demethylation, as well as other enzymatic activities that link cellular metabolism to gene regulation. Additionally, it affects the functioning of enzymes that influence epigenetic modifications of chromatin: ten–eleven translocation hydroxylases involved in DNA demethylation and the Jumonji C domain containing lysine demethylases, which are the major histone demethylases. Thus, it regulates gene expression.
Collagen synthesis regulator: AKG is an obligatory co-substrate for 2-oxoglutarate-dependent dioxygenases, which catalyse hydroxylation reactions on various types of substrates. It regulates the activity of prolyl-4 hydroxylase, which controls the biosynthesis of collagen, a component of bone tissue.
Antioxidant: The role of alpha-ketoglutarate (KG) in the detoxification of reactive oxygen species (ROS) has only recently begun to be appreciated. This ketoacid neutralizes ROS in an NADPH-independent manner with the concomitant formation of succinate and CO₂.
Nitrogen metabolism: Alpha-ketoglutarate is a precursor of glutamine which contributes to muscle repair, prevents protein catabolism, improves nitrogen retention, functions as an immunomodulatory molecule, and takes part in proper function of intestines.
HIF pathway modulation: AKG also affects the functioning of prolyl hydroxylases, which, in turn, influences the function of the hypoxia-inducible factor, an important transcription factor in cancer development and progression.

5.3 The Histidine-to-Alpha-Ketoglutarate Metabolic Link

There is a direct biochemical relationship between histidine and AKG via catabolism. The main pathway of HIS catabolism begins with deamination catalyzed by histidase to urocanate and leads through 4-imidazolone-5-propionate and FIGLU to glutamate. Histidine is degraded by conversion to glutamate, and then oxidised to alpha-ketoglutarate by glutamate dehydrogenase. Thus, histidine is a biochemical upstream precursor of AKG. Research on microorganisms has demonstrated this relationship under oxidative stress conditions: to probe this attribute of KG in living systems, the significance of histidine metabolism in the model organism Pseudomonas fluorescens, challenged by hydrogen peroxide (H₂O₂), was evaluated. This amino acid does contribute to KG homeostasis and appears to be earmarked for the production of KG during oxidative stress.

This endogenous metabolic relationship provides the mechanistic rationale for combining the two molecules in a single supplement: the use of histidine alpha-ketoglutaric acid as a combined ingredient in nutritional products is based on the hypothesis that the pairing may enhance absorption and synergistically support metabolic pathways. This hypothesis, however, has not been rigorously tested in dedicated human clinical trials for the combined salt form specifically.

6. Established Mechanisms of Action

The mechanisms described below are derived from research on the individual components (histidine and AKG), as independent human mechanistic studies of the combined histidine alpha-ketoglutaric acid salt are not available in the peer-reviewed literature reviewed.

Energy Metabolism

Alpha-ketoglutarate (AKG) is a key molecule for cellular energy and protein synthesis. AKG functions as an antioxidant, in nitrogen and ammonia balance, as well as in epigenetic and immune regulation. Histidine, through its catabolism to glutamate and subsequently to AKG, feeds directly into the TCA cycle, where α-KG plays a central role in the TCA cycle, where it undergoes oxidative decarboxylation to form succinyl-CoA. This reaction, catalyzed by α-ketoglutarate dehydrogenase, is a key regulatory step that links amino acid catabolism to ATP production.

Nitrogen and Protein Balance

By virtue of its role in the amino acid synthesis pathway, AKG exerts strong regulatory control over protein metabolism. Previous studies demonstrated its potency in conserving endogenous glutamine pools and increasing glutamine synthesis, which have particular benefits in clinical nutrition and metabolic care by countering trauma-induced catabolism. Histidine, when administered as a supplement, indirectly supports muscle nitrogen economy. Glutamine released from muscles can be effectively utilized by several tissues and exert favourable effects on gut integrity, the immune system, and protein balance. Hence, it may be suggested that some positive effects of HIS administration are mediated by GLN and that HIS supplementation is an alternative way to achieve GLN supplementation.

Antioxidant Defense

Both components contribute to antioxidant capacity by distinct mechanisms. AKG scavenges reactive oxygen species (ROS) non-enzymatically in an NADPH-independent reaction producing succinate and CO₂. The role of alpha-ketoglutarate in the detoxification of reactive oxygen species (ROS) has only recently begun to be appreciated. This ketoacid neutralizes ROS in an NADPH-independent manner with the concomitant formation of succinate and CO₂. Histidine exerts antioxidant activity through the imidazole ring's ability to quench singlet oxygen and scavenge hydroxyl radicals, and indirectly through its role as a substrate for carnosine synthesis. The beneficial effects of histidine may occur through the metabolism of histidine to carnosine or histamine, metabolic products that have roles in allergic responses, gastric secretions, cognitive function, oxidative stress, and cardiometabolic health.

Epigenetic Regulation

AKG occupies a central role as a co-substrate for a large family of 2-oxoglutarate-dependent dioxygenases (2-OGDDs), which include the TET enzymes responsible for DNA demethylation and the Jumonji domain-containing histone demethylases. Changes in intracellular AKG concentrations can therefore alter the methylation state of DNA and histones, affecting gene expression. Prior studies have shown that α-KG can enhance stem cell pluripotency, modulate immune responses, and influence cancer cell plasticity. This mechanism is increasingly cited in the context of aging biology.

Collagen and Bone Matrix

AKG is an obligatory co-substrate for 2-oxoglutarate-dependent dioxygenases, which catalyse hydroxylation reactions on various types of substrates. It regulates the activity of prolyl-4 hydroxylase, which controls the biosynthesis of collagen, a component of bone tissue. This mechanism provides a theoretical basis for AKG's observed effects on bone density.

Ammonia Detoxification

The most of ammonia produced during HIS catabolism to glutamate and by glutamate dehydrogenase reaction in the liver is undoubtedly detoxified to urea, as indicated by increased urea concentration in the blood. Increased α-ketoglutarate production by glutamate dehydrogenase reaction may activate gluconeogenesis. At pharmacological doses, this pathway is relevant to hepatic metabolism.

7. Scientific Evidence by Area of Use

Important caveat: Direct clinical studies on histidine alpha-ketoglutarate as a unique ingredient in nutritional products remain limited. The following sections therefore report separately on (a) clinical evidence for L-histidine supplementation and (b) clinical evidence for AKG supplementation. Claims that the combination produces effects beyond those of either component alone are not yet supported by independent human clinical trials.

7.1 Metabolic Syndrome, Insulin Resistance, and Obesity

Evidence level: Moderate (human RCT data available for histidine; limited human data for AKG alone).

Currently, HIS and/or HIS-containing dipeptides are investigated to prevent fatigue during strenuous exercise and for therapy in ageing-related disorders, metabolic syndrome, atopic dermatitis, ulcers, inflammatory bowel diseases, ocular diseases, and neurological disorders. A notable randomized controlled trial (Feng et al., Diabetologia, 2013;56(5):985–994) investigated histidine supplementation in obese women with metabolic syndrome. Feng RN, Niu YC, Sun XW, et al. showed that histidine supplementation improves insulin resistance through suppressed inflammation in obese women with the metabolic syndrome, in a randomised controlled trial (Diabetologia 2013;56(5):985-94). HIS or CAR supplementation has been shown to be effective on insulin resistance, plasma lipid levels, and inflammatory markers and has delayed the development of atherosclerosis in several rodent models of diabetes and metabolic syndrome.

From a cardiovascular perspective, histidine has been found to decrease the risk of metabolic and cardiovascular diseases. A population-based analysis published in PMC (2024) reported that this amino acid is nutritionally vital for mammals, possessing distinct biochemical and physiological characteristics; these properties give a strong theoretical rationale for the use of histidine as a versatile dietary supplement for various health issues. Currently, histidine and histidine-containing peptides are under scrutiny for their effectiveness in preventing ageing-related disorders such as atherosclerosis, neurological disorders (including Alzheimer's disease), cancer, metabolic syndrome (MetS), and people with obesity.

7.2 Rheumatoid Arthritis

Evidence level: Weak (one historical RCT with no significant benefit; observational association only).

A significant decrease in the blood HIS concentration has been observed in patients with rheumatoid arthritis. This prompted early supplementation trials. However, although individuals with rheumatoid arthritis appear to have reduced levels of histidine in the blood, this does not prove that taking histidine will help. One study designed to evaluate this question directly found no significant benefit. Further, the study was conducted in the 1970s. The evidence for histidine supplementation as a treatment for rheumatoid arthritis is therefore currently insufficient. The Cochrane Library lists the 1977 Pinals et al. randomized, placebo-controlled, double-blind trial as the primary study on this question.

7.3 Anaemia Associated with Renal Failure

Evidence level: Preliminary (some clinical evidence from older studies).

Studies have established that histidine is beneficial in treating metabolic disorders. Research has also shown that supplementation with histidine for anemia associated with kidney failure or for patients on dialysis is beneficial. The clinical rationale is that histidine is a conditionally essential amino acid in patients with chronic renal failure — in uremic patients, histidine cannot be synthesized in adequate amounts. Histidine is considered essential for infants. In contrast, it is considered non-essential for adults, except for uremic patients.

7.4 Nitrogen Balance, Protein Catabolism, and Surgical Recovery

Evidence level: Moderate for AKG component (multiple human clinical studies, mainly in surgical/critical care populations); insufficient for the combined salt.

Evidence suggests that alpha-ketoglutarate supplementation can support nitrogen balance, muscle protein synthesis, and gut health, particularly in catabolic or critically ill patients. US Patent 5,646,187 describes the utility of α-ketoglutarate in treating critically ill patients for improving protein synthesis capacity, preserving lean body mass and maintaining energy status in skeletal muscle. Similarly, WO 89/03688 discloses the use of α-ketoglutarate to increase glutamine content in postoperative patients. A 2021 review in a peer-reviewed journal noted that these functions of AKG have a beneficial effect on the treatment of diseases such as in the heart, brain, liver, and skeletal muscle.

Human clinical studies published in the 1980s and 1990s investigated AKG and related alpha-keto acid compounds in postoperative patients and those with protein-wasting conditions, primarily using ornithine alpha-ketoglutarate (OKG) rather than histidine alpha-ketoglutarate specifically. Clinical studies in older adults and patients recovering from surgery have found that AKG supplementation can improve nitrogen balance (a marker of muscle maintenance), support bone density, and aid recovery.

7.5 Bone Density and Aging

Evidence level: Preliminary human data (small trials); robust animal data; growing research in aging biology.

Recently, alpha-ketoglutarate (AKG) has been introduced as a potential anti-aging metabolite that can control several functions in organisms, thereby increases longevity and improves healthspan. Some of the more recent human trials using Calcium-Alpha-Ketoglutarate (Ca-AKG), a more stable form of AKG, have shown small but measurable improvements in bone strength and biological aging markers for middle-aged adults. Preclinical studies in rodents and invertebrates have reported lifespan extension and improved physiological resilience, but human trials remain limited in both size and duration, thereby restricting conclusions regarding its long-term safety and efficacy in clinical settings.

Evidence from long-term supplementation trials suggests that although AKG could beneficially modulate age-related molecular pathways such as mTOR and AMPK, its biological effects vary considerably among species and individuals, reflecting limited universality and potential interspecies translational gaps. Moreover, AKG does not directly activate these pathways but rather alters metabolic states that indirectly influence their activity, suggesting its regulatory role may be secondary or context-dependent.

7.6 Osteoarthritis

Evidence level: Preclinical only; no adequate human clinical trials.

While recent studies suggest that AKG possesses therapeutic potential in animal models of OA, including the attenuation of cartilage degeneration, suppression of lipid peroxidation, promotion of autophagy, and enhancement of cell survival, the majority of these findings are derived from in vitro experiments or animal studies. There is a clear absence of systematic clinical research on the use of AKG or its derivatives for the treatment of OA. Therefore, to evaluate its safety and efficacy in humans, further high-quality clinical trials are needed.

7.7 Organ Preservation and Cardioplegia (HTK Solution)

Evidence level: Strong (robust clinical evidence in surgical context, though not an oral dietary supplement).

The most rigorously studied application of a histidine-and-ketoglutarate-containing formulation is the HTK organ preservation and cardioplegia solution. HTK solution is intended for perfusion and flushing of donor liver, kidney, heart, lung and pancreas prior to removal from the donor and for preserving these organs during hypothermic storage and transport to the recipient. Use of HTK solution was expanded to preservation of the liver, kidney, and pancreas as well as the heart and lung. The protective effect of HTK solution is based on the high buffering capacity provided by histidine and its low electrolyte content, thus restricting tissue acidosis.

A 2022 systematic review and meta-analysis published in the Journal of Cardiothoracic Surgery examined 12 randomized controlled trials (n = 1,327 patients) comparing HTK solution with multidose cardioplegia in cardiac surgeries. This review included 12 trials (n = 1327). HTK solution has resulted significantly in shorter intensive care unit stay (MD = −0.09; 95% CI [−0.15, −0.03], p = 0.006), and shorter hospital stay. Moreover, the patients who received the HTK solution had significantly lower levels of creatine kinase (after 4–7 h (MD = −157.52; 95% CI [−272.31, −42.19], p = 0.007), and 24 h (MD = −136.62; 95% CI [−267.20, −6.05], p = 0.04)), as well as creatine kinase muscle brain band (after 44–48 h (MD = −3.35; 95% CI [−5.69, −1.02], p = 0.005)). HTK solution had the same efficacy and safety as other cardioplegic solutions in most of the clinical parameters. Furthermore, the solution showed superiority in fastening the recovery and protecting the myocardium at the biochemical level. HTK solution provides longer myocardial protection; therefore, it limits surgical interruption.

This clinical evidence, though robust, pertains exclusively to HTK solution used in a hospital surgical setting and should not be extrapolated to oral dietary supplementation of histidine alpha-ketoglutaric acid.

7.8 Atopic Dermatitis

Evidence level: Preliminary (small human study).

A small clinical trial (Tan et al., Clin. Cosmet. Investig. Dermatol. 2017;10:403–411) investigated L-histidine supplementation in atopic dermatitis, focusing on histidine's role as a substrate for filaggrin (a key structural protein of the skin barrier). HIS-containing dipeptides are investigated for therapy in ageing-related disorders, metabolic syndrome, atopic dermatitis, ulcers, inflammatory bowel diseases, ocular diseases, and neurological disorders. The evidence base for this indication remains small and preliminary.

7.9 Cancer Biology (Preclinical)

Evidence level: Preclinical only; not established for clinical use.

AKG is also involved in cell protection against oxidative stress and cyanide poisoning. It can also influence bone strength and density and inhibit carcinogenesis induced by oncometabolites or hypoxia by activating enzymes from the 2-OGDD family (2-oxoglutarate-dependent dioxygenases). Regarding histidine, dietary supplementation of the amino acid histidine has demonstrable benefits in various clinical conditions. Recent work in a pediatric leukemia mouse model exposed a surprising potential application of histidine supplementation for cancer therapy enhancement. These findings demand a deeper reassessment of the physiological effects and potential drawbacks of histidine supplementation. A recent study determined that histidine catabolism could improve the efficacy of methotrexate in treating cancer by increasing the sensitivity of cancer cells to methotrexate. Before histidine can be used for cancer therapies, the appropriate dose and duration of histidine supplementation need to be identified. All such findings are preclinical and should not be interpreted as clinical recommendations.

8. Body Systems and Health Areas Associated With This Ingredient

Musculoskeletal system: Nitrogen balance support, muscle protein synthesis, carnosine substrate supply (via histidine), collagen synthesis (via AKG and prolyl hydroxylase), bone density (AKG component).
Cardiovascular system: Myocardial protection (HTK solution context); histidine's association with reduced cardiovascular and metabolic disease risk; L-histidine has the ability to decrease blood pressure in spontaneously hypertensive rats via diminishing sympathetic output through the central histamine H3 receptor and enhancing nitric oxide in the rostral ventrolateral medulla (animal data).
Hepatic system: AKG's role in ammonia detoxification and nitrogen disposal; liver support in critical care.
Immune system: Histidine supplementation has been shown to support immune function and antioxidant status, while alpha-ketoglutaric acid has demonstrated benefits in preserving muscle mass, supporting gut health, and improving nitrogen balance, particularly in catabolic states or during intense physical activity.
Gastrointestinal system: AKG supports intestinal mucosal integrity; histidine-derived glutamine supports gut function. An RCT published in J. Infect. Dis. (2005) studied L-histidine-supplemented oral rehydration solution for cholera (Rabbani et al., J Infect Dis 2005;191(9):1507-14).
Endocrine/metabolic system: Insulin resistance, lipid metabolism, metabolic syndrome.
Nervous system: Histidine as a histamine precursor; histamine's role as a neurotransmitter; emerging research on cognitive health.
Dermatological system: Histidine as a substrate for filaggrin in the skin barrier; atopic dermatitis research.
Epigenome: AKG as a co-substrate for DNA and histone demethylases; aging biology implications.

9. Dosage Forms and Dosages Reported in Studies

Dosages are reported only as stated in the cited sources. These do not constitute recommendations.

L-Histidine (Oral Supplementation — Clinical Studies)

A dosage of 4.0–4.5 g/d was deemed safe, with no adverse side effects reported, by the Dietary Reference Intakes for Energy, Carbohydrate, Fiber, Fat, Fatty Acids, Cholesterol, Protein, and Amino Acids.
The Feng et al. (2013) RCT in obese women with metabolic syndrome used oral L-histidine supplementation in addition to dietary counseling (dose details reported in the Diabetologia publication).
The rodent studies reviewed by Holecek et al. (PMC 8549891) used histidine dissolved in drinking water at doses of 0.5 g/l (low HIS), 2 g/l (high HIS) or 0 g/l (control) for 4 weeks.

Alpha-Ketoglutarate (Oral Supplementation — Clinical Studies and Reviews)

AKG's safety record is strong, with doses up to 6 grams per day generally well tolerated, according to a recent narrative review.
Regarding related amino acid alpha-ketoglutarate salts in controlled-release formulations (arginine AKG as precedent), patented formulation ranges cited sizes of about 50 mg to about 1,000 mg generally used, preferably in the range of about 100 mg to about 500 mg and more preferably about 300 mg.
The HTK solution used in cardiac surgery contains a high HIS concentration of 198 mM and potassium hydrogen 2-ketoglutarate at 1 mmol/L, administered intravenously; these concentrations are not applicable to oral supplementation.

Histidine Alpha-Ketoglutaric Acid (Combined Salt — Oral Supplement)

No peer-reviewed human clinical trial has been identified that studied the combined histidine alpha-ketoglutaric acid salt as a distinct oral supplement at a defined dose. Despite the need for further research to fully elucidate its specific effects and optimal dosing in human nutrition, histidine alpha-ketoglutarate remains a promising ingredient.

10. Safety Considerations and Interactions

General Safety of L-Histidine

Signs of toxicity, mutagenic activity, and allergic reactions or peptic ulcers have not been reported, although HIS is a histamine precursor. In toxicological animal studies, a 2-year toxicity and carcinogenicity of histidine HCl was studied in 100 male and female rats. Rats were fed histidine mixed in a diet up to concentrations of 1.1 g histidine/(kg body weight·d). No neoplastic changes or histidine-related changes in tumor incidence were found.

At high doses in humans: at high intakes of histidine (>24 g/d), studies report adverse effects of histidine such as decreased serum zinc and cognitive impairment. There is limited research on the effects of histidine intake at doses between 4.5 and 24 g/d, and thus, a tolerable upper level has not been established. In human studies, there have been no studies to test the tolerable upper level of histidine supplementation.

In animal models, high amounts of histidine intake resulted in reduced plasma zinc and copper, growth retardation, hepatomegaly, and hypercholesterolemia. Of concern should be findings of hepatic enlargement and increases in ammonia and glutamine and of decrease in branched-chain amino acids (valine, leucine).

A relevant concern at very high pharmacological doses of histidine is ammonia generation. In one study, the administration of a HIS load in a dose corresponding to the HIS load in human cardiac surgery to rats markedly increased ammonia levels and impaired the energy status of the liver and skeletal muscle. This finding is context-specific to the large intravenous doses used in cardiac surgery and may not be directly applicable to oral dietary supplementation at typical doses.

General Safety of Alpha-Ketoglutarate

Supplements containing alpha-ketoglutarate are available over-the-counter, but their benefits for any use are not well defined. Although they seem to be well tolerated, there is not enough research to know what common side effects they may cause. AKG is regarded as a safe supplement with the potential to extend healthspan and even compress morbidity.

Electrolyte Disturbance (Surgical Context)

When the HTK solution (which contains histidine and ketoglutarate) was administered intravenously during cardiac surgery, clinically significant electrolyte disturbance was observed: all patients were normonatremic at start of surgery. All patients developed hyponatremia after administration of HTK solution with a significant drop of serum sodium of 15 mmol/L (p < 0.01). This effect is specific to the large-volume intravenous administration used in cardiac surgery and does not apply to oral supplementation.

Drug Interactions

Some products contain alpha-ketoglutarate along with other substances, such as arginine, ornithine, and calcium. These other substances may cause different effects, side effects, and interactions. Histidine's role as a histamine precursor raises a theoretical concern regarding potential interaction with histamine-modulating medications (antihistamines, monoamine oxidase inhibitors), though no specific interaction studies for oral histidine alpha-ketoglutaric acid have been published. Histidine's metal-chelating properties may theoretically alter the absorption of co-administered zinc, copper, or iron supplements or drugs. Determining tolerance to histidine supplementation has been limited by small sample sizes and, more importantly, a lack of a clear biomarker for histidine supplementation. The U-shaped curve of circulating zinc concentrations with histidine supplementation could be exploited as a relevant biomarker for supplemental histidine tolerance.

Cancer Therapy Context

The safety of high doses of histidine and its relevant metabolic fates in the human body are discussed in the literature. Comprehensive preclinical evidence for safety and efficacy of histidine supplementation is still lacking. In the specific context of cancer treatment, histidine's potential to enhance methotrexate sensitivity means that histidine supplementation in oncology patients receiving methotrexate could have unintended pharmacological consequences and requires careful investigation before any clinical application.

Regulatory Status

The FDA has not reviewed alpha-ketoglutarate for safety and effectiveness. Histidine alpha-ketoglutaric acid as a combined entity does not appear on the European Food Safety Authority (EFSA) list of authorized health claims for amino acid-containing supplements as a distinct entity. It circulates primarily as a supplement ingredient in jurisdictions where amino acid compounds are regulated as dietary supplements rather than drugs.

11. Evidence Summary and Research Gaps

Some preclinical and clinical studies have explored the effects of alpha-ketoglutarate and histidine, both separately and in combination. Evidence suggests that alpha-ketoglutarate supplementation can support nitrogen balance, muscle protein synthesis, and gut health, particularly in catabolic or critically ill patients. Histidine supplementation has been associated with antioxidant properties and potential benefits for metabolic health. However, direct clinical studies on histidine alpha-ketoglutarate as a unique ingredient in nutritional products remain limited.

These studies are still early, but together they suggest that AKG could play a supportive role in promoting healthy aging, especially when taken in a bioavailable form. Despite the growing excitement about the study results, the review is careful to point out that AKG research in humans is still young.

Key unresolved questions include: (1) whether the combined salt form provides pharmacokinetic advantages over the individual components taken separately; (2) the optimal oral dosage range and dosing schedule for the combined ingredient; (3) whether the endogenous metabolic relationship between histidine and AKG (histidine being a biochemical precursor of AKG) translates into meaningful physiological synergy when both are supplied exogenously; and (4) long-term safety data in diverse human populations. Well controlled studies on adverse effects of increased intake of specific amino acids on humans are rare.